Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGNZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for LIGAND PHARMS BETA CVR (LGNZZ) centers on regulatory documents associated with Ligand Pharmaceuticals Incorporated, the issuer identified in related filings. Although LGNZZ itself is not detailed in the excerpted registration table, the name links it to the same company whose common stock trades under the symbol LGND on The Nasdaq Global Market.
One highlighted filing is a Form 8-K in which Ligand Pharmaceuticals Incorporated reports entry into a Third Amendment to its Credit Agreement. This document explains that the company, together with certain subsidiaries as guarantors, amended a credit facility with a group of lenders and Citibank, N.A. as administrative agent, swingline lender, and letter of credit issuer. The amendment extends the maturity date and adjusts a minimum consolidated EBITDA covenant, illustrating how the issuer’s direct financial obligations and covenants evolve over time.
On this page, users can review current reports on Form 8-K and related exhibits that describe material definitive agreements and the creation or modification of direct financial obligations. These filings provide insight into the company’s borrowing arrangements, financial maintenance requirements, and relationships with its lenders.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain the key points of lengthy agreements and technical disclosures. Instead of reading an entire amendment or credit agreement, users can rely on concise explanations that highlight the nature of the obligation, the roles of the parties, and the main covenant changes. Real-time updates from EDGAR help ensure that new filings, such as additional amendments or related exhibits, are incorporated as they become available.
Ligand Pharmaceuticals director John W. Kozarich reported selling a total of 467 shares of common stock on April 1, 2026 in a series of open-market transactions. The reported weighted-average sale prices ranged from about $199.97 to $204.26 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the sales, Kozarich directly holds 42,253 shares of Ligand Pharmaceuticals common stock.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon exercised stock options and sold the resulting shares. He exercised 5,000 Employee Stock Options at an exercise price of $52.27 per share, receiving 5,000 shares of common stock.
On the same date, he sold all 5,000 shares in multiple open-market transactions at weighted-average prices ranging from about $198.40 to $204.82 per share, under a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, he directly holds 41,382 shares of Ligand common stock.
LGND Rule 144 notice discloses reported dispositions of Common stock. The filing lists an issuer broker entry at UBS Financial Services and shows multiple reported sales by John Kozarich of 467 shares on 01/02/2026, 02/02/2026, and 03/02/2026 with reported amounts $88,532.51, $91,490.02, and $93,632.38 respectively.
Director John L. LaMattina of LIGAND PHARMACEUTICALS INC exercised stock options and sold the resulting shares. He exercised a non-qualified stock option for 2,161 shares of common stock at an exercise price of $114.15 per share, then sold 2,161 shares of common stock in an open-market transaction at $200.76 per share on the same day. Following these transactions, he directly holds 30,724 shares of Ligand common stock. The option position associated with these 2,161 shares is now fully exercised.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza received equity awards as part of his compensation. He was granted stock options covering 23,527 shares of common stock at an exercise price of $202.55 per share, expiring on March 2, 2036. These options vest as to 12.5% of the underlying shares six months after the grant date, then in 42 substantially equal monthly installments.
He also received 4,933 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest in three substantially equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, subject to continued service. Delivery of shares on each vesting date will be deferred under the company’s Nonqualified Deferred Compensation Plan. Following the RSU grant, he directly owns 37,945 shares of common stock.
Ligand Pharmaceuticals Chief Executive Officer Todd C. Davis reported equity awards consisting of stock options and restricted stock units. He received options to buy 50,058 shares of common stock at an exercise price of $202.55 per share, expiring on March 2, 2036.
The option grant vests as to 12.5% of the underlying shares six months after the grant date and then in 42 substantially equal monthly installments. Davis also received 10,495 restricted stock units, each representing one share of common stock, which vest in three equal annual installments on February 15, 2027, February 15, 2028, and February 15, 2029, with delivery of shares deferred under a company plan.
LGND reported an insider sale. Stephen L. Sabba reported the sale of 2,034 common shares on 03/03/2026 with an aggregate figure shown as $409,851.00 in the filing. The notice also records an earlier exercised block of 1,000 shares on 03/05/2024 noted as "Exercised Shares" for cash.
Ligand Pharmaceuticals’ Chief Legal Officer and Secretary Andrew Reardon reported a set of planned insider transactions in company stock. On March 4, 2026, he exercised employee stock options for 5,000 shares of common stock and then sold 5,000 common shares in a series of open-market trades.
The sales were executed at weighted-average prices disclosed in ranges between approximately $197.58 and $208.97, under a Rule 10b5-1 trading plan adopted on November 24, 2025. After these transactions, Reardon directly holds 36,869 common shares and 54,444 options, with the underlying option grant vesting over time.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza reported option exercises and share sales in company stock. On March 4, 2026, he exercised employee stock options covering 2,073 shares of common stock and then sold 13,423 shares in open-market transactions.
The sales were executed at weighted-average prices generally between $198.37 and $208.95 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 21,662 shares of Ligand common stock.